Oxygen Self-Generating Nanoreactor Mediated Ferroptosis Activation and Immunotherapy in Triple-Negative Breast Cancer

被引:70
|
作者
Li, Ke
Xu, Kun [1 ]
He, Ye [2 ]
Yang, Yulu [1 ]
Tan, Meijun [1 ]
Mao, Yulan [1 ]
Zou, Yanan [1 ]
Feng, Qian [1 ]
Luo, Zhong [3 ]
Cai, Kaiyong [1 ]
机构
[1] Chongqing Univ, Minist Educ, Key Lab Biorheol Sci & Technol, Coll Bioengn, Chongqing 400044, Peoples R China
[2] Duke Univ, Thomas Lord Dept Mech Engn & Mat Sci, Durham, NC 27708 USA
[3] Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
self-supplying nanoreactor; ferroptosis; immunotherapy; O2; production; GSH depletion; triple-negative breast cancer; CELL-DEATH; THERAPY; HYPOXIA; NANOPARTICLES; HIF-1-ALPHA; RESISTANCE;
D O I
10.1021/acsnano.2c10893
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The hypoxia microenvironment of solid tumors poses a technological bottleneck for ferroptosis and immunotherapy in clinical oncology. Nanoreactors based on special physiological signals in tumor cells are able to avoid various tumor tolerance mechanisms by alleviating the intracellular hypoxia environment. Herein we reported a nanoreactor Cu2-xSe that enabled the conversion of Cu elements between Cu+ and Cu2+ for the generation of O2 and the consumption of intracellular GSH content. Furthermore, to enhance the catalytic and ferroptosis-inducing activities of the nanoreactors, the ferroptosis agonist Erastin was loaded on the ZIF-8 coating on the surface of Cu2-xSe to up-regulate the expression of NOX4 protein, increase the intracellular H2O2 content, catalyze the Cu+ to produce O2 and activate ferroptosis. In addition, the nanoreactors were simultaneously surface functionalized with PEG polymer and folic acid molecules, which ensured the in vivo blood circulation and tumor-specific uptake. In vitro and in vivo experiments demonstrated that the functionalized self-supplying nanoreactors can amplify the ability to generate O2 and consume intracellular GSH via the interconversion of Cu elements Cu+ and Cu2+, and impair the GPX4/GSH pathway and HIF-1 alpha protein expression. At the same time, by alleviating the intracellular hypoxia environment, the expression of miR301, a gene in the secreted exosomes was decreased, which ultimately affected the phenotype polarization of TAMs and increased the content of IFN gamma secreted by CD8+ T cells, which further promoted the ferroptosis induced by Erastin-loaded nanoreactors. This combined therapeutic strategy of activating the tumor immune response and ferroptosis via self-supplying nanoreactors provides a potential strategy for clinical application.
引用
收藏
页码:4667 / 4687
页数:21
相关论文
共 50 条
  • [41] Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
    Denkert, Carsten
    Schneeweiss, Andreas
    Rey, Julia
    Karn, Thomas
    Hattesohl, Akira
    Weber, Karsten E.
    Rachakonda, Sivaramakrishna
    Braun, Michael
    Huober, Jens
    Jank, Paul
    Sinn, Hans-Peter
    Zahm, Dirk-Michael
    Felder, Barbel
    Hanusch, Claus
    Teply-Szymanski, Julia
    Marme, Frederik
    Fehm, Tanja
    Thomalla, Jorg
    V. Sinn, Bruno
    Stiewe, Thorsten
    Marczyk, Michal
    Blohmer, Jens-Uwe
    van Mackelenbergh, Marion
    Schem, Christian
    Staib, Peter
    Link, Theresa
    Muller, Volkmar
    Stickeler, Elmar
    Stover, Daniel G.
    Solbach, Christine
    Metzger-Filho, Otto
    Jackisch, Christian
    Geyer Jr, Charles E.
    Fasching, Peter A.
    Pusztai, Lajos
    Nekljudova, Valentina
    Untch, Michael
    Loibl, Sibylle
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [42] Novel immunotherapy approach for metastatic triple-negative breast cancer
    Griffin, Paul
    Jain, Riya
    Le, Sean
    Rajapakse, Kyle
    Miller, Wilson
    Andarawewa, Kumari
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [43] Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer
    McArthur, Heather
    ONCOLOGY-NEW YORK, 2019, 33 (04): : 137 - 140
  • [44] Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
    Mediratta, Karan
    El-Sahli, Sara
    D'Costa, Vanessa
    Wang, Lisheng
    CANCERS, 2020, 12 (12) : 1 - 36
  • [45] Efficacy of immunotherapy is attenuated with age in triple-negative breast cancer
    McAllister, Sandra S.
    Sceneay, Jaclyn
    Laszewski, Tyler
    DeCristo, Molly
    Ubellacker, Jessalyn
    Wilson, Kristin
    Qin, Yuanbo
    Hutchinson, John
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
    Zheng, Yiwen
    Li, Shujin
    Tang, Hongchao
    Meng, Xuli
    Zheng, Qinghui
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Correlation between ferroptosis-related genes and PDL-1 immunotherapy in triple-negative breast cancer
    Tian, Wuguo
    Zhao, Jianjie
    Luo, Donglin
    ASIAN JOURNAL OF SURGERY, 2023, 46 (10) : 4595 - 4597
  • [48] Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy
    Lin Li
    Bingjun Sun
    Jin Sun
    Lin Chen
    Zhonggui He
    Chinese Chemical Letters, 2024, 35 (10) : 374 - 378
  • [49] Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy
    Li, Lin
    Sun, Bingjun
    Sun, Jin
    Chen, Lin
    He, Zhonggui
    CHINESE CHEMICAL LETTERS, 2024, 35 (10)
  • [50] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863